Bibliografia Osmeda® Diet

• Irene Palenca, Maria Masulli, Sara Rurgo, Giovanni Sarnelli, Giuseppe Esposito, Targeting metabolic syndrome with ALIAmides: A novel multi-mechanistic approach, Biomedicine & Pharmacotherapy, Volume 192, 2025, 118611,

• G. Esposito, E. Capoccia, F. Turco, I. Palumbo, J. Lu, A. Steardo, R. Cuomo, G. Sarnelli, L. Steardo, Palmitoylethanolamide improves colon inflammation through an enteric glia/toll like receptor 4-dependent PPAR-α activation, Gut 63 (8) (2014 Aug) 1300–1312, https://doi.org/10.1136/gutjnl-2013-305005. Epub 2013 Sep 30. PMID: 24082036.

• Seguella L, Corpetti C, Lu J, Pesce M, Franzin SB, Palenca I, Zilli A, Vincenzi M, Caprioli D, Paytuví-Gallart A, Sanseverino W, Rurgo S, Sarnelli G, Esposito G. Oleoylethanolamide-producing Lactobacillus paracasei F19 improves metabolic and behavioral disorders by restoring intestinal permeability and microbiota-gut-brain axis in high-fat diet-induced obese male mice. Brain Behav Immun. 2025 Jul;127:25-44. doi: 10.1016/j.bbi.2025.02.014. Epub 2025 Feb 21. PMID: 39988008.

• Romano A, Micioni Di Bonaventura MV, Gallelli CA, Koczwara JB, Smeets D, Giusepponi ME, De Ceglia M, Friuli M, Micioni Di Bonaventura E, Scuderi C, Vitalone A, Tramutola A, Altieri F, Lutz TA, Giudetti AM, Cassano T, Cifani C, Gaetani S. Oleoylethanolamide decreases frustration stress-induced binge-like eating in female rats: a novel potential treatment for binge eating disorder. Neuropsychopharmacology. 2020 Oct;45(11):1931-1941. doi: 10.1038/s41386-020-0686-z. Epub 2020 Apr 30. PMID: 32353860;
PMCID: PMC7609309

• L. Seguella, C. Corpetti, J. Lu, M. Pesce, S.B. Franzin, I. Palenca, A. Zilli, M. Vincenzi, D. Caprioli, A. Paytuví-Gallart, W. Sanseverino, S. Rurgo, G. Sarnelli, G. Esposito, Oleoylethanolamide-producing lactobacillus paracasei F19 improves metabolic and behavioral disorders by restoring intestinal permeability and microbiota-gut-brain axis in high-fat diet-induced obese Male mice, Brain Behav. Immun.
127 (2025 Feb 21) 25–44, https://doi.org/10.1016/j. bbi.2025.02.014. Epub ahead of print. PMID: 39988008.

• B. Costa, F. Comelli, I. Bettoni, M. Colleoni, G. Giagnoni, The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: involvement of CB(1), TRPV1 and PPARgamma receptors and neurotrophic factors, Pain 139 (3) (2008 Oct 31) 541–550, https:// doi.org/10.1016/j. pain.2008.06.003. Epub 2008 Jul 3. PMID: 18602217

• V. Di Marzo, S. Petrosino, Endocannabinoids and the regulation of their levels in health and disease, Curr. Opin. Lipido 18 (2) (2007 Apr) 129–140, https://doi.org/ 10.1097/MOL.0b013e32803dbdec. PMID: 17353660.

• R.G. Pertwee, Endocannabinoids and their pharmacological actions, Handb. Exp. Pharm. 231 (2015) 1–37, https://doi.org/10.1007/978-3-319-20825-1_1. PMID: 26408156.

• G. Sarnelli, M. Pesce, L. Seguella, J. Lu, E. Efficie, J. Tack, F.D. Elisa De Palma, A. D’Alessandro, G. Esposito, Impaired duodenal palmitoylethanolamide release underlies Acid-Induced mast cell activation in functional dyspepsia, Cell Mol. Gastroenterol. Hepatol. 11 (3) (2021) 841–855, https://doi.org/10.1016/j. jcmgh.2020.10.001. Epub 2020 Oct 14.
PMID: 33065341; PMCID: PMC7858681.

• Medoro, S. Davinelli, F. Fogacci, S. Alfieri, D. Tiso, A.F.G. Cicero, G. Scapagnini, Palmitoylethanolamide in postmenopausal metabolic syndrome: current evidence and clinical perspectives, Nutrients 16 (24) (2024 Dec 13) 4313, https://doi.org/ 10.3390/nu16244313. PMID: 39770936; PMCID: PMC11677032.

• Annunziata, C. Pirozzi, A. Lama, M. Senzacqua, F. Comella, A. Bordin, A. Monnolo, A. Pelagalli, M.C. Ferrante, M.P. Mollica, A. Iossa, E. De Falco, G. Mattace Raso, S. Cinti, A. Giordano, R. Meli, Palmitoylethanolamide promotes White-to-Beige conversion and metabolic reprogramming of adipocytes: contribution of PPAR-α, Pharmaceutics 14 (2)
(2022 Jan 31) 338, https://doi.org/ 10.3390/pharmaceutics14020338. PMID: 35214069; PMCID: PMC8880285

• Michael Camilleri, Giovanni Sarnelli, Viola Andresen, Beverley Greenwood-Van Meerveld, Colin W. Howden, Angelo A. Izzo, Karen L. Jones. Pharmacological, Pharmacokinetic, and Pharmacogenomic Aspects of Disorders of Gut–Brain Interaction. Gastroenterology, Volume 170, Issue 6, 2026, Pages 1152-1170, ISSN 0016-5085, https://doi.org/10.1053/j.gastro.2026.02.010.

• M. Ahmadian, J.M. Suh, N. Hah, C. Liddle, A.R. Atkins, M. Downes, R.M. Evans, PPARγ signaling and metabolism: the good, the bad and the future, Nat. Med 19 (5) (2013 May) 557–566, https://doi.org/10.1038/nm.3159. Epub 2013
May 7. PMID: 23652116; PMCID: PMC3870016.

• Clayton, P., Hill, M., Bogoda, N., Subah, S., & Venkatesh, R. (2021). Palmitoylethanolamide: A Natural Compound for Health Management. International journal of molecular sciences, 22(10), 5305. https://doi.org/10.3390/ijms22105305

• Bahari H, Jazinaki MS, Aghakhani L, Hatami A, Rahnama I, Malekahmadi M. Oleoylethanolamide supplementation on cardiometabolic health: a systematic review and meta-analysis of randomized controlled trials. Front Nutr. 2025 May 21;12:1553288. doi: 10.3389/fnut.2025.1553288. PMID: 40469682; PMCID: PMC12133512.

• R. Valenzuela, P. Illesca, F. Echeverría, A. Espinosa, M. Á. Rincón-Cervera, M. Ortiz, M. C. Hernandez-Rodas, A. Valenzuela and L. A. Videla, Molecular adaptations underlying the beneficial effects of hydroxytyrosol in the pathogenic alterations induced by a high-fat diet in mouse liver: PPAR-α and Nrf2 activation, and NF-κB down-regulation, Food Funct., 2017, 8, 1526-1537

• Fytili, C.; Nikou, T.; Tentolouris, N.; Tseti, I.K.; Dimosthenopoulos, C.; Sfikakis, P.P.; Simos, D.; Kokkinos, A.; Skaltsounis, A.L.; Katsilambros, N.; et al. Effect of Long-Term Hydroxytyrosol Administration on Body Weight, Fat Mass and Urine Metabolomics: A Randomized Double-Blind Prospective Human Study. Nutrients 2022, 14, 1525.

• Araújo, J.R., Tomas, J., Brenner, C., Sansonetti, P.J., 2017. Impact of high-fat diet on the intestinal microbiota and small intestinal physiology before and after the onset of obesity. Biochimie. 141, 97–106. https://doi.org/10.1016/j.biochi.2017.05.019.
• Barandouzi, Z.A., Starkweather, A.R., Henderson, W.A., Gyamfi, A., Cong, X.S., 2020. Altered composition of gut microbiota in depression: a systematic review. Front. Psychiatry. 11, 541. https://doi.org/10.3389/fpsyt.2020.00541.

• B´egin-Heick, N., 1996. Of mice and women: the beta 3-adrenergic receptor leptin and obesity. Biochem. Cell Biol. Biochim. Biol. Cell. 74 (5), 615–622. https://doi.org/ 10.1139/o96-066.

• Bessac, A., Cani, P.D., Meunier, E., Dietrich, G., Knauf, C., 2018. Inflammation and Gutbrain axis during type 2 diabetes: focus on the crosstalk between intestinal immune cells and enteric nervous system. Front. Neurosci. 12, 725. https://doi.org/10.3389/fnins.2018.00725.

• Bocher, V., Chinetti, G., Fruchart, J.-C., Staels, B., 2002. Role of the peroxisome proliferator-activated receptors (PPARS) in the regulation of lipids and inflammation control. J. Soc. Biol. 196 (1), 47–52.

• Bowen, K.J., Kris-Etherton, P.M., Shearer, G.C., West, S.G., Reddivari, L., Jones, P.J.H., 2017. Oleic acid-derived oleoylethanolamide: A nutritional science perspective. Prog. Lipid Res. 67, 1–15. https://doi.org/10.1016/j.plipres.
2017.04.001.

• Bravo, J.A., et al., 2011. Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve. Proc. Natl. Acad. Sci. U. S. A. 108 (38), 16050–16055. https://doi. org/10.1073/ pnas.1102999108.

• Cani, P.D., et al., 2016. Endocannabinoids–at the crossroads between the gut microbiota and host metabolism. Nat. Rev. Endocrinol. 12 (3), 133–143. https://doi.org/ 10.1038/nrendo.2015.211.

• Castanon, N., Luheshi, G., Lay´e, S., 2015. Role of neuroinflammation in the emotional and cognitive alterations displayed by animal models of obesity. Front. Neurosci. 9, 229. https://doi.org/10.3389/fnins.2015.00229.

• Chen, X., et al., 2020. Alteration of the gut microbiota associated with childhood obesity by 16S rRNA gene sequencing. PeerJ. 8, e8317.

• Cox, A.J., West, N.P., Cripps, A.W., 2015. Obesity, Inflammation, and the Gut Microbiota. Lancet Diabetes Endocrinol. 3 (3), 207–215. https://doi.org/10.1016/ S2213-8587(14)70134-2.

• Crovesy, L., Masterson, D., Rosado, E.L., 2020. Profile of the gut microbiota of adults with obesity: a systematic review. Eur. J. Clin. Nutr. 74 (9), 1251–1262. https://doi. org/10.1038/s41430-020-0607-6.

• Di Paola, M., et al., 2018. Oleoylethanolamide treatment affects gut microbiota composition and the expression of intestinal cytokines in Peyer’s patches of mice. Sci. Rep. 8, 14881. https://doi.org/10.1038/s41598-018-32925-x.